{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:54:20Z","timestamp":1793386460102,"version":"4.5.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T00:00:00Z","timestamp":1664928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To describe clinical phenotypes and prognosis of neurological autoimmunity related to glutamic acid decarboxylase 65 (GAD65) antibodies in China.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>In this retrospective observational study from Peking Union Medical College Hospital, we identified patients with neurological disorders related to GAD65 antibodies (cell-based assay) from May 2015 to September 2021. Clinical manifestations, immunotherapy responsiveness, and outcomes were collected after obtaining informed consent from all patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fifty-five patients were included: 40 (72.73%) were women and initial neurological symptoms developed at 42(34-55) years of age. The median time to the nadir of the disease was 5 months (range from 1 day to 48 months). The clinical syndromes included limbic encephalitis (LE) or epilepsy (Ep) (<jats:italic>n<\/jats:italic>= 34, 61.82%), stiff-person syndromes (SPS) (<jats:italic>n<\/jats:italic>= 18, 32.73%), autoimmune cerebellar ataxia (ACA) (<jats:italic>n<\/jats:italic>= 11, 20%), and overlap syndrome in eight (14.55%) patients. Thirty-two (58.2%) patients had comorbidities of other autoimmune diseases, including Hashimoto thyroiditis (<jats:italic>n<\/jats:italic>= 17, 53.13%), T1DM (<jats:italic>n<\/jats:italic>= 11, 34.78%), vitiligo (<jats:italic>n<\/jats:italic>= 6, 18.75%), and others (n=5, 15.63%). Two (3.64%) patients had tumors, including thymoma and small cell lung cancer. Fifty-one (92.7%) patients received first-line immunotherapy (glucocorticoids and\/or IV immunoglobulin), and 4 (7.3%) received second-line immunotherapy (rituximab). Long-term immunotherapy (mycophenolate mofetil) was administered to 23 (41.8%) patients. At the median time of 15 months (IQR 6\u201333.75 month, range 3\u201396 month) of follow-up, the patients' median modified Rankin Score (mRS) had declined from 2 to 1. Thirty-eight (70.4%) patients experienced clinical improvement (mRS declined \u22651), 47 (87%) had favorable clinical outcomes (mRS \u22642), and nine were symptom-free (16.7%). The sustained response to immunotherapy ranged from 7\/15 (63.63%) in ACA patients and 22\/34 (64.7%) in LE\/Ep patients to 14\/17 (82.35%) in SPS patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>LE\/Ep was the most common neurological phenotype of GAD65 antibody neurological autoimmunity in our cohort. Most patients had comorbidities of other autoimmune diseases, but underlying tumors were rare. Most patients responded to immunotherapy. However, the long-term prognosis varied among different clinical phenotypes.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.990553","type":"journal-article","created":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T08:39:26Z","timestamp":1664959166000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Neurological disorders associated with glutamic acid decarboxylase 65 antibodies: Clinical spectrum and prognosis of a cohort from China"],"prefix":"10.3389","volume":"13","author":[{"given":"Lin","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menglin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mange","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixue","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhi","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/s0197-0186(99)00063-7","article-title":"Regional distribution and relative amounts of glutamate decarboxylase isoforms in rat and mouse brain","volume":"35","author":"Sheikh","year":"1999","journal-title":"Neurochem Int."},{"key":"B2","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/j.1471-4159.2006.03741.x","article-title":"Evidence that GAD 65 mediates increased GABA synthesis during intense neuronal activity in vivo: GAD 65 mediated GABA synthesis during seizures","volume":"97","author":"Patel","year":"2006","journal-title":"J Neurochem."},{"key":"B3","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/j.1471-4159.1991.tb08211.x","article-title":"Two forms of the gamma-aminobutyric acid synthetic enzyme glutamate decarboxylase have distinct intraneuronal distributions and cofactor interactions","volume":"56","author":"Kaufman","year":"1991","journal-title":"J Neurochem."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1056\/NEJM198804213181602","article-title":"Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus","volume":"318","author":"Solimena","year":"1988","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e696","DOI":"10.1212\/NXI.0000000000000696","article-title":"Neurologic syndromes related to anti-GAD65: Clinical and serologic response to treatment","volume":"7","author":"Mu\u00f1oz-Lopetegi","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B6","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1136\/jnnp-2020-325275","article-title":"Clinical spectrum of high-titre GAD65 antibodies","volume":"92","author":"Budhram","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1111\/ene.14005","article-title":"Clinical spectrum of glutamic acid decarboxylase antibodies in a Taiwanese population","volume":"26","author":"Kuo","year":"2019","journal-title":"Eur J Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11910-017-0758-6","article-title":"The New classification of seizures by the international league against epilepsy 2017","volume":"17","author":"Fisher","year":"2017","journal-title":"Curr Neurol Neurosci Rep."},{"key":"B9","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/archneurol.2011.991","article-title":"Stiff-man syndrome and variants: clinical course, treatments, and outcomes","volume":"69","author":"McKeon","year":"2012","journal-title":"Arch Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1111\/j.1468-1331.2011.03609.x","article-title":"Prevalence and immunological spectrum of temporal lobe epilepsy with glutamic acid decarboxylase antibodies","volume":"19","author":"Falip","year":"2012","journal-title":"Eur J Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.seizure.2020.05.008","article-title":"Low rate of glutamic acid decarboxylase 65 (GAD-65) antibodies in chronic epilepsy","volume":"80","author":"Tizazu","year":"2020","journal-title":"Seizure."},{"key":"B12","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.yebeh.2018.01.021","article-title":"Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy","volume":"80","author":"Daif","year":"2018","journal-title":"Epilepsy & Behavior."},{"key":"B13","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s10072-021-05281-4","article-title":"Rivera Garrido FJ, Alba Suarez EM, Tallon Barranco A. Serum glutamate decarboxylase antibodies and neurological disorders: when to suspect their association?","volume":"43","author":"Lacruz Ballester","year":"2022","journal-title":"Neurol Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"756668","DOI":"10.3389\/fneur.2021.756668","article-title":"Case report: multisystem autoimmune and overlapping GAD65-antibody-associated neurological disorders with beneficial effect of epilepsy surgery and rituximab treatment","volume":"12","author":"Dimova","year":"2021","journal-title":"Front Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.4065\/81.9.1207","article-title":"Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction","volume":"81","author":"Pittock","year":"2006","journal-title":"Mayo Clin Proc."},{"key":"B16","doi-asserted-by":"crossref","first-page":"279","DOI":"10.33549\/physiolres.930485","article-title":"Anti-GAD-positive patients with type 1 diabetes mellitus have higher prevalence of autoimmune thyroiditis than anti-GAD-negative patients with type 1 and type 2 diabetes mellitus","volume":"53","author":"B\u00e1rov\u00e1","year":"2004","journal-title":"Physiol Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jneuroim.2017.05.019","article-title":"Autoimmune encephalitis associated with vitiligo?","volume":"310","author":"Haitao","year":"2017","journal-title":"J Neuroimmunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1001\/jamaneurol.2015.0749","article-title":"Paraneoplastic neurological syndromes and glutamic acid decarboxylase antibodies","volume":"72","author":"Ari\u00f1o","year":"2015","journal-title":"JAMA Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41582-020-0359-x","article-title":"antibodies in neurological disorders \u2014 insights and challenges","volume":"16","author":"Graus","year":"2020","journal-title":"Nat Rev Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00234-018-1976-6","article-title":"findings in glutamic acid decarboxylase associated autoimmune epilepsy","volume":"60","author":"Fredriksen","year":"2018","journal-title":"Neuroradiology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1097\/RLU.0000000000003379","article-title":"18F-FDG PET\/CT in initial diagnosis and treatment response evaluation of anti-NMDAr and anti-GAD dual antibody autoimmune encephalitis","volume":"46","author":"Seniaray","year":"2021","journal-title":"Clin Nucl Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/jon.12874","article-title":"Brain FDG-PET findings in glutamic acid decarboxylase antibody-associated epilepsy","volume":"31","author":"Mongay-Ochoa","year":"2021","journal-title":"Journal of Neuroimaging."},{"key":"B23","doi-asserted-by":"publisher","first-page":"102339","DOI":"10.1016\/j.jaut.2019.102339","article-title":"The immunobiology of autoimmune encephalitides","volume":"104","author":"Alexopoulos","year":"2019","journal-title":"J Autoimmun."},{"key":"B24","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1515\/med-2021-0220","article-title":"Efficacy and safety of therapeutic plasma exchange in stiff person syndrome","volume":"16","author":"Czempik","year":"2021","journal-title":"Open Medicine."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1001\/jamaneurol.2015.2378","article-title":"Responses to and outcomes of treatment of autoimmune cerebellar ataxia in adults","volume":"72","author":"Jones","year":"2015","journal-title":"JAMA Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12868-020-00561-9","article-title":"Intravenous methylprednisolone or immunoglobulin for anti-glutamic acid decarboxylase 65 antibody autoimmune encephalitis: which is better?","volume":"21","author":"Li","year":"2020","journal-title":"BMC Neurosci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1017\/cjn.2016.13","article-title":"Limbic encephalitis associated with GAD65 antibodies: brief review of the relevant literature","volume":"43","author":"Gagnon","year":"2016","journal-title":"Can J Neurol Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/ana.25002","article-title":"double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome","volume":"82","author":"Dalakas","year":"2017","journal-title":"Ann Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e1088","DOI":"10.1212\/NXI.0000000000001088","article-title":"Rituximab treatment and long-term outcome of patients with autoimmune encephalitis: real-world evidence from the generate registry","volume":"8","author":"Thaler","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B30","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/RHU.0b013e3181e931fa","article-title":"Stiff-person syndrome: persistent elevation of glutamic acid decarboxylase antibodies despite successful treatment with rituximab","volume":"16","author":"Bacorro","year":"2010","journal-title":"J Clin Rheumatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s42399-019-00185-z","article-title":"New-onset refractory status epilepticus with underlying autoimmune etiology: a case report","volume":"2","author":"Brunker","year":"2020","journal-title":"SN Compr Clin Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"100396","DOI":"10.1016\/j.ebr.2020.100396","article-title":"Super refractory status epilepticus secondary to anti-GAD antibody encephalitis successfully treated with aggressive immunotherapy","volume":"14","author":"Jaafar","year":"2020","journal-title":"Epilepsy Behav Rep."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s00415-010-5476-9","article-title":"Treatment of anti-glutamic acid decarboxylase antibody-associated limbic encephalitis with mycophenolate mofetil","volume":"257","author":"Saidha","year":"2010","journal-title":"J Neurol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1007\/s00415-020-09807-2","article-title":"Long-term outcomes in temporal lobe epilepsy with glutamate decarboxylase antibodies","volume":"267","author":"Joubert","year":"2020","journal-title":"J Neurol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"577289","DOI":"10.1016\/j.jneuroim.2020.577289","article-title":"Clinical features and immunotherapy outcomes of anti-glutamic acid decarboxylase 65 antibody-associated neurological disorders","volume":"345","author":"Chengyu","year":"2020","journal-title":"J Neuroimmunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1001\/archneur.58.2.225","article-title":"Cerebellar ataxia with anti\u2013glutamic acid decarboxylase antibodies: study of 14 patients","volume":"58","author":"Honnorat","year":"2001","journal-title":"Arch Neurol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jns.2009.09.004","article-title":"Acute limbic encephalitis and glutamic acid decarboxylase antibodies: a reality?","volume":"287","author":"Blanc","year":"2009","journal-title":"J Neurol Sci."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.990553\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T01:39:11Z","timestamp":1677029951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.990553\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,5]]},"references-count":37,"alternative-id":["10.3389\/fneur.2022.990553"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.990553","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,5]]},"article-number":"990553"}}